What the Study Found (In Plain English)
Published in Clinical pharmacology in drug development (2025), this randomized controlled trial evaluating 50 human participants investigated: Glucose and lipid metabolism disorders significantly contribute to vascular damage and poor outcomes in patients with diabetes. Key clinical takeaway: The findings indicated that the improvement in glucose and lipid metabolism disorders, as well as the reduction in microinflammation, was significantly greater in the observation group compared to the control group (P 2 or greater (95% confidence interval, 0.6%-1.2; P < .001).
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Clinical pharmacology in drug development, 2025-12-15; N = 50; Rigor 88/100): The findings indicated that the improvement in glucose and lipid metabolism disorders, as well as the reduction in microinflammation, was significantly greater in the observation group compared to the control group (P 2 or greater (95% confidence interval, 0.6%-1.2; P < .001).
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.